TABLE 3

Estimates of the 5-Dose DTaP Series and Tdap Pertussis VE and Duration of Protection

Evaluation TypeVaccine StatusCaseControlOR (95% CI)VE %95% CI
DTaPn = 263n = 726
 Overall VEUnvaccinateda1911RefRefRef
5 doses DTaP on-scheduleb2447150.16 (0.06–0.42)8458–94
 Time since fifth-DTaP dose, moUnvaccinateda1911RefRefRef
<1219950.10 (0.03–0.29)9071–97
12–23211440.07 (0.02–0.21)9379–98
24–35281190.11 (0.04–0.31)8969–96
36–47331200.13 (0.05–0.37)8763–95
48–59601130.24 (0.09–0.67)7633–91
60–83831240.33 (0.12–0.90)6810–88
Tdapn = 244n = 714
 Overall VEUnvaccinatedc103163RefRefRef
1 Tdap dose on-scheduled1415510.30 (0.20–0.46)7054–81
 Time since Tdap dose, moUnvaccinatedc103163RefRefRef
<12352020.24 (0.15–0.40)7660–85
12–23511800.37 (0.22–0.64)6337–78
24–46551690.44 (0.23–0.84)5616–77
  • ORs were adjusted for medical home and age range for the DTaP VE analyses and for medical home and birth year for the Tdap analyses. The Tdap analyses focused on participants who had received acellular vaccines only for the childhood pertussis vaccine series.

  • a Unvaccinated DTaP participants had no recorded pertussis-containing vaccines in their chart and had parental confirmation of nonreceipt.

  • b Vaccinated DTaP participants had received 5 doses of DTaP on-schedule, defined as doses 1 to 3 at age <12 months, dose 4 at age 1 to <2 years, dose 5 at age 4 to <7 years.

  • c Unvaccinated Tdap participants had no recorded Tdap vaccine in their chart and had parental confirmation of nonreceipt.

  • d Vaccinated Tdap participants had received 1 dose of Tdap at or after age 11 years.